Literature DB >> 8301200

Comparison of antibody activity against various microorganisms in intravenous immunoglobulin preparations determined by ELISA and opsonic assay.

P S Hiemstra1, J Brands-Tajouiti, R van Furth.   

Abstract

In the present study the level of antimicrobial antibodies and the phagocytosis-promoting activity in immunoglobulin preparations produced for intravenous use were assessed. The level of antibodies directed against various microorganisms in six immunoglobulin preparations was determined by using an enzyme-linked immunosorbent assay (ELISA) and was shown to be either equal to or higher than that of pooled normal human serum. All preparations were able to promote phagocytosis of Staphylococcus aureus, Escherichia coli K12, and Streptococcus pyogenes by human granulocytes. Substantial differences among the various preparations in antibody activity were noted. In particular, Intraglobulin, chemically modified by beta-propiolactone treatment, exhibited little activity in both the ELISA and the phagocytosis assay. In contrast, IVIG SRC, Gamimmune, Sandoglobulin (treated at low pH in presence or absence of trace amounts of pepsin), and Gammagard (treated by ion-exchange chromatography) showed good activity in both assays. Comparison of the results of the ELISA and phagocytosis assay for the various preparations indicated a good correlation except for S. aureus with a moderate (strain 42D) or high (strain Cowan I) protein A content. These data indicate that the antibody activity of immunoglobulin preparations against various microorganisms determined by ELISA can be used to predict their opsonic activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8301200

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  8 in total

1.  Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product.

Authors:  M Trautmann; T K Held; M Susa; M A Karajan; A Wulf; A S Cross; R Marre
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

2.  Successful treatment of severe streptococcal toxic shock syndrome with a combination of intravenous immunoglobulin, dexamethasone and antibiotics.

Authors:  C H Chiu; J T Ou; K S Chang; T Y Lin
Journal:  Infection       Date:  1997 Jan-Feb       Impact factor: 3.553

3.  Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model.

Authors:  N A Barekzi; K A Poelstra; A G Felts; I A Rojas; J B Slunt; D W Grainger
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

4.  Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations.

Authors:  Malgorzata G Mikolajczyk; Nelydia F Concepcion; Theresa Wang; Douglas Frazier; Basil Golding; Carl E Frasch; Dorothy E Scott
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

5.  Effective combination therapy for invasive pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model.

Authors:  L De Hennezel; F Ramisse; P Binder; G Marchal; J M Alonso
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

6.  Role of Yops in inhibition of phagocytosis and killing of opsonized Yersinia enterocolitica by human granulocytes.

Authors:  L G Visser; A Annema; R van Furth
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

7.  Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections.

Authors:  Nazir A Barekzi; Adrian G Felts; Kornelis A Poelstra; Jeffrey B Slunt; David W Grainger
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

Review 8.  Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms.

Authors:  Lloyd S Miller; Vance G Fowler; Sanjay K Shukla; Warren E Rose; Richard A Proctor
Journal:  FEMS Microbiol Rev       Date:  2020-01-01       Impact factor: 16.408

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.